Summary of project PR002343

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002343. The data can be accessed directly via it's Project DOI: 10.21228/M8S548 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Project ID: PR002343
Project DOI:doi: 10.21228/M8S548
Project Title:Untargeted lipidomics of combination gemcitabine/paclitaxel attenuated (CombAT) PDAC cells
Project Summary:Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with few treatment options and poor survivability. In this work we sought to characterise metabolic adaptations to gemcitabine (GEMC)-based chemotherapy exposure to discover new therapeutic targets for improving treatment efficacy. This project examined the impact of combination gemcitabine/paclitaxel resistance on the lipidomics of Panc1 and MiaPaCa2 PDAC cell lines, finding upregulated de novo lipogenesis in both cell lines.
Institute:Victor Chang Cardiac Research Institute
Last Name:Hancock
First Name:Sarah
Address:Level 7 Lowy Packer Building, 405 Liverpool Street, Darlinghurst, NSW 2010, Australia
Email:s.hancock@victorchang.edu.au
Phone:+61414537526

Summary of all studies in project PR002343

Study IDStudy TitleSpeciesInstituteAnalysis
(* : Contains Untargted data)
Release
Date
VersionSamplesDownload
(* : Contains raw data)
ST003760 Untargeted lipidomics of combination gemcitabine/paclitaxel attenuated (CombAT) PDAC cells Homo sapiens Victor Chang Cardiac Research Institute MS 2025-03-21 1 32 Uploaded data (11.5G)*
  logo